Impact of COVID-19 lockdown on visual acuities of patients with macular diseases.
Author: Abid Ali (United Kingdom)
Co-authors: Cara Mitchell, Faruque Ghanchi
Purpose
To describe visual outcome of patients who were undergoing intravitreal injection treatment for Age related macular degeneration (AMD), Diabetic macular edema (DME) and retinal vein occlusion (RVO) when COVID-19 pandemic hit UK.
Setting/Venue
Macula clinic of a large teaching hospital in UK.
Methods
A retrospective observational study was conducted on 500 randomly selected patients receiving intravitreal therapy for AMD, DMO or RVO at the macula clinic at the time of UK national lockdown (16th March 2020) for COVID- 19. Patients commencing intravitreal treatment post lockdown, those not attending a face to face follow-up and patients who died post lockdown were excluded from the study. The last recorded visual acuity pre-lockdown was compared to the visual acuity recorded at first visit post lockdown. A significant reduction in vision was defined as a drop of 5 or more EDTRS letters. Where vision loss was recorded, patient’s visual acuity at last visit (at least 12 weeks) after further intravitreal injection treatment was recorded. Delayed treatment was defined as >2 weeks delay than planned interval. Patient demography, indication for injection and total number of injections were also collected from Electronic medical records (EMR).
Results
Data was collected from 500 randomly selected patients receiving intravitreal therapy at our dedicated macula service 180 patients were excluded: 141 new presentation post lockdown, 30 no face to face visit, 9 died. The remaining 320 (133 Male , 187 Female, mean age 76), consisted of 175 nAMD, 67 RVO , 68 DME and 10 other macular conditions. A total of 116 patients of 320 (36.25%) had loss of >5 letters at the last visit post lockdown. The highest proportion was AMD patients, 72 of 175 AMD (41.14%). While 26 of 67(38.8%) RVO patients and 17 of 68 (25%) DME patients had lost >5 letters. AMD patients were less likely to regain visual acuity to pre lockdown level despite further treatment compared to RVO and DMO patients.
Conlusions
COVID-19 related lockdown caused disruption of clinical services, resultant delays in intravitreal treatment causes significant loss of vision in patients with macular diseases. The impact is highest for AMD (41%), followed by RVO (38%) and DME (25%). In patients with AMD, it is more difficult to regain vision with further treatment. It is important to recognise potential of irreversible loss of vision in macular patients due to disruption of services. Efforts should be made to continue intravitreal injection treatments in future lockdowns.